2 minutes reading time (368 words)

Nab-Paclitaxel Noninferior to Docetaxel in Advanced Non-Small Cell Lung Cancer

NSCLC cells.

In patients with previously treated advanced non-small cell lung cancer (NSCLC), nanoparticle albumin-bound (nab)–paclitaxel is noninferior to docetaxel, according to results of the phase 3 J-AXEL trial presented this past weekend at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer.

Single-agent docetaxel is considered the second-line standard of care for patients with advanced NSCLC. However, recent studies have shown that nab-paclitaxel also demonstrates promising antitumor activity in this patient population.

In the multicenter, randomized, open-label trial, a team of researchers led by Atsushi Nakamura, MD, PhD, of the Department of Pulmonary Medicine at Sendai Kousei Hospital in Sendai, Japan, investigated the noninferiority of nab-paclitaxel to docetaxel in patients with advanced NSCLC. The trial enrolled 503 patients previously treated with cytotoxic chemotherapy. Patients were randomized in a 1:1 ratio to receive docetaxel 60 mg/m2 docetaxel on Day 1 or nab-paclitaxel 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle until disease progression or unacceptable toxicity. The study's primary end point was overall survival.

Nab-paclitaxel produced a higher median overall survival compared with docetaxel (16.2 vs 13.6 months), although the difference did not reach statistical significance. Median progression-free survival was also increased with nab-paclitaxel compared with docetaxel (4.2 vs 3.4 months), a statistically significant improvement. Patients receiving nab-paclitaxel experienced a higher objective response rate compared with docetaxel (29.9% vs 15.4%), with consistent benefit across tumor histology subgroups. Patients receiving nab-paclitaxel experienced a lower incidence of grade 3/4 febrile neutropenia compared with those in the docetaxel arm (2.0% vs 22.1%), but the incidence of peripheral sensory neuropathy was substantially higher with nab-paclitaxel (10% vs 1%).

"The trial showed that nab-paclitaxel was noninferior to docetaxel in terms of overall survival," conclude Dr. Nakamura and colleagues in their presentation abstract. "Nab-paclitaxel should thus be considered a standard treatment option for previously treated patients with advanced NSCLC."

For More Information

Nakamura A et al (2021). Phase III study comparing nab-paclitaxel with docetaxel in patients with previously treated advanced non-small-cell lung cancer (ID 3317). IASLC World Conference on Lung Cancer. Abstract OA03.05.

Image credit: Yale Rosen. Licensed under CC BY-SA 2.0


Related Posts

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.